Table 2. Molecules with similar pharmacological profiles to predicted statin sensitivity across cell lines.

Pharmacological profiles from CCLE and Sanger Center drug sensitivity data were used to predict combination therapy with statins. Molecules with positive correlation and FDR Q-Value < .05 were included. For CCLE profiles, IC₅₀ was used as a proxy for sensitivity, and for Sanger center profiles, the area under the dose-response curve (AUC) was used.

Drug Name	Target	Correlation	P Value
Dabrafenib	BRAF	0.456976009	2.38E-18
PLX-4720	BRAF	0.376159659	4.97E-13
(5Z)-7-Oxozeaenol	TAK1	0.376014976	8.61E-13
SB590885	BRAF	0.340372121	4.32E-09
TW 37	BCL2, BCL-XL, MCL1	0.27305505	1.89E-06
Piperlongumine	NF-κB	0.226445462	0.000199099
Cisplatin	DNA crosslinker	0.233847531	0.000250235
Lestauritinib	FLT3, JAK2, NTRK1, NTRK2, NTRK3	0.218300548	0.000905096
Elesclomol	HSP90	0.206861021	0.002058482
Refametinib	MEK1, MEK2	0.183970201	0.004239963
Bleomycin	dsDNA break induction	0.183339449	0.004370418
Temsirolimus	MTOR	0.182232337	0.01021699
Nutlin-3a (-)	MDM2	0.176424024	0.010924768
Selumetinib	MEK1, MEK2	0.165658468	0.010924768
AZ628	BRAF	0.296949736	0.011550955
PD0325901	MEK1, MEK2	0.173101761	0.011550955
Serdemetan	MDM2	0.164726002	0.011550955
Trametinib	MEK1, MEK2	0.166312205	0.011550955
Docetaxel	Microtubule stabilizer	0.169092858	0.013420485
BX796	TBK1, PDK1 (PDPK1), IKK, AURKB, AURKC	0.167710541	0.013718152
Embelin	XIAP	0.157305764	0.016974867
FH535	PPARγ, PPARΔ	0.154672573	0.02034349
YK-4-279	RNA helicase A	0.158950401	0.026108609
Rucaparib	PARP1, PARP2	0.147699505	0.027477555
CI-1040	MEK1, MEK2	0.152967932	0.032836113
SN-38	TOP1	0.140036378	0.040080871
CHIR-99021	GSK3A, GSK3B	0.135343422	0.041404418